JP2025138641A5 - - Google Patents

Info

Publication number
JP2025138641A5
JP2025138641A5 JP2025088861A JP2025088861A JP2025138641A5 JP 2025138641 A5 JP2025138641 A5 JP 2025138641A5 JP 2025088861 A JP2025088861 A JP 2025088861A JP 2025088861 A JP2025088861 A JP 2025088861A JP 2025138641 A5 JP2025138641 A5 JP 2025138641A5
Authority
JP
Japan
Prior art keywords
drawings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025088861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025138641A (ja
Filing date
Publication date
Priority claimed from JP2022515487A external-priority patent/JP2022547167A/ja
Application filed filed Critical
Publication of JP2025138641A publication Critical patent/JP2025138641A/ja
Publication of JP2025138641A5 publication Critical patent/JP2025138641A5/ja
Pending legal-status Critical Current

Links

JP2025088861A 2019-09-10 2025-05-28 Kras変異型がんを治療する方法 Pending JP2025138641A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962898249P 2019-09-10 2019-09-10
US62/898,249 2019-09-10
US201962931608P 2019-11-06 2019-11-06
US62/931,608 2019-11-06
JP2022515487A JP2022547167A (ja) 2019-09-10 2020-09-10 Kras変異型がんを治療する方法
PCT/US2020/050206 WO2021050732A1 (en) 2019-09-10 2020-09-10 Methods of treating kras mutant cancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022515487A Division JP2022547167A (ja) 2019-09-10 2020-09-10 Kras変異型がんを治療する方法

Publications (2)

Publication Number Publication Date
JP2025138641A JP2025138641A (ja) 2025-09-25
JP2025138641A5 true JP2025138641A5 (https=) 2026-01-22

Family

ID=74866476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515487A Pending JP2022547167A (ja) 2019-09-10 2020-09-10 Kras変異型がんを治療する方法
JP2025088861A Pending JP2025138641A (ja) 2019-09-10 2025-05-28 Kras変異型がんを治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022515487A Pending JP2022547167A (ja) 2019-09-10 2020-09-10 Kras変異型がんを治療する方法

Country Status (8)

Country Link
US (1) US20220331401A1 (https=)
EP (1) EP4028044A4 (https=)
JP (2) JP2022547167A (https=)
KR (1) KR20220061997A (https=)
CN (1) CN114375197A (https=)
AU (1) AU2020346820A1 (https=)
CA (1) CA3149872A1 (https=)
WO (1) WO2021050732A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス, インコーポレイテッド アザキナゾリン汎KRas阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106790A1 (en) * 2016-12-06 2018-06-14 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same
WO2018128745A1 (en) * 2017-01-06 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same

Similar Documents

Publication Publication Date Title
JP2025138632A5 (https=)
JP2025138641A5 (https=)
JP2024116190A5 (https=)
JP2024129139A5 (https=)
JP2024161376A5 (https=)
JP2022191211A5 (https=)
JP2024114921A5 (https=)
JP2025176106A5 (https=)
JP2023171775A5 (https=)
JP2025118629A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2023166402A5 (https=)
JP2024059739A5 (https=)
JP2023145572A5 (https=)
JP2026004279A5 (https=)
JP2025160243A5 (https=)
JP2022543046A5 (https=)
JP2025098156A5 (https=)
JP2023181322A5 (https=)
JP2025094038A5 (https=)
JP2025090801A5 (https=)
JP2024149687A5 (https=)
JP2024045126A5 (https=)
JP2025081323A5 (https=)